BIOVENTUS INC. - CLASS A COMMON STOCK

Bioventus to Present at the Canaccord Genuity Musculoskeletal Conference

16 Mar 2022 07:00:00 By Nasdaq GlobeNewswire

Bioventus Reports Fourth Quarter and Full Year 2021 Financial Results; Introduces Full Year 2022 Financial Guidance

10 Mar 2022 07:00:03 By Nasdaq GlobeNewswire

Bioventus Receives 510(k) Clearance for StimRouter Pain Management Device

01 Mar 2022 07:00:01 By Nasdaq GlobeNewswire

Bioventus Appoints Mark Singleton as Chief Financial Officer

28 Feb 2022 07:00:00 By Nasdaq GlobeNewswire

Bioventus to Report Fourth Quarter and Fiscal Year 2021 Financial Results on March 10, 2022

22 Feb 2022 07:00:01 By Nasdaq GlobeNewswire

Bioventus Announces Preliminary Fourth Quarter and Full-Year 2021 Revenue

11 Jan 2022 07:00:00 By Nasdaq GlobeNewswire

Bioventus to Present at the 40th Annual J.P. Morgan Healthcare Conference

28 Dec 2021 07:00:00 By Nasdaq GlobeNewswire

Bioventus Appoints Michelle McMurry-Heath to Board of Directors

21 Dec 2021 09:25:00 By Nasdaq GlobeNewswire

Bioventus Receives US FDA Clearance for BoneScalpel® Access™

20 Dec 2021 08:30:00 By Nasdaq GlobeNewswire

Bioventus to Expand Operations and Manufacturing in Memphis

18 Nov 2021 08:45:00 By Nasdaq GlobeNewswire

Bioventus Announces Chief Financial Officer Transition Plan

15 Nov 2021 07:30:01 By Nasdaq GlobeNewswire

Bioventus Reports Third Quarter Results; Updates Full-Year 2021 Financial Guidance

09 Nov 2021 07:00:02 By Nasdaq GlobeNewswire

Sharon Klugewicz Joins Bioventus as Senior Vice President, Quality and Regulatory Affairs

01 Nov 2021 08:30:00 By Nasdaq GlobeNewswire

Bioventus Completes the Acquisition of Misonix

29 Oct 2021 08:25:18 By Nasdaq GlobeNewswire

Bioventus to Release Third Quarter of Fiscal Year 2021 Financial Results on November 9, 2021

27 Oct 2021 16:15:00 By Nasdaq GlobeNewswire

Bioventus and Misonix Stockholders Approve the Acquisition of Misonix by Bioventus

26 Oct 2021 16:15:00 By Nasdaq GlobeNewswire

BIOVENTUS INC. and MISONIX, INC. Announce Election Deadline of 5:00 p.m. New York City Time, on October 25, 2021 for Misonix Stockholders to Elect Form of Merger Consideration

18 Oct 2021 08:00:01 By Nasdaq GlobeNewswire

DUROLANE® Among High-Molecular Weight Hyaluronic Acid Treatments Linked to Significant Improvements in Knee Osteoarthritis Pain by American Academy of Orthopaedic Surgeons

20 Sep 2021 08:30:00 By Nasdaq GlobeNewswire

Bioventus Proceeds with Option Structure Agreement with CartiHeal

30 Aug 2021 07:30:00 By Nasdaq GlobeNewswire

Bioventus Invests in Trice Medical Minimally Invasive Technologies

25 Aug 2021 16:05:00 By Nasdaq GlobeNewswire